title: Recombinant human growth hormone, but not insulin-like growth factor-I, enhances central fat loss in postmenopausal women undergoing a diet and exercise program.
abstract: We examined the effect of recombinant human growth hormone (rhGH) and/or recombinant human insulin-like growth factor-I (rhIGF-l) on regional fat loss in postmenopausal women undergoing a weight loss regimen of diet plus exercise. Twenty-seven women aged 59-79 years, 20-40% above ideal body weight, completed a 12-week program consisting of resistance training 2 days/week and walking 3 days/week, while consuming a diet that was 500 kcal/day less than that required for weight maintenance. Participants were randomly assigned in a double-blind fashion to receive rhGH (0.025 mg/kg BW/day; n = 7), rhIGF-I (0.015 mg/kg BW/day; n = 7), rhGH + rhIGF-I (n = 6), or placebo (PL; n = 7). Regional and whole body fat mass were determined by dual X-ray absorptiometry. Body fat distribution was assessed by the ratios of trunk fat-to-limb fat (TrF/LimbF) and trunk fat-to-total fat (TrF/TotF). Limb and trunk fat decreased in all groups (p < 0.01). For both ratios of fat distribution, the rhGH treated group experienced an enhanced loss of truncal compared to peripheral fat (p < 0.01), with no significant change for those administered rhIGF-I or PL. There was no association between change in fat distribution and indices of cardiovascular disease risk as determined by serum lipidilipoprotein levels and maximal aerobic capacity. These results suggest that administration of rhGH facilitates a decrease in central compared to peripheral fat in older women undertaking a weight loss program that combines exercise and moderate caloric restriction, although no beneficial effects are conferred to lipid/lipoprotein profiles. Further, the effect of rhGH is not enhanced by combining rhGH with rhIGF-I administration. In addition, rhIGF-I does not augment the loss of trunk fat when administered alone.
authors.affiliation: Epidemiology, Demography, and Biometry Program, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA. dtaaffe@hms.uq.edu.au
authors.forename: D R
authors.initials: DR
authors.lastname: Taaffe
authors.forename: J L
authors.initials: JL
authors.lastname: Thompson
authors.forename: G E
authors.initials: GE
authors.lastname: Butterfield
authors.forename: A R
authors.initials: AR
authors.lastname: Hoffman
authors.forename: R
authors.initials: R
authors.lastname: Marcus
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D002149:Energy Intake; D015914:Estrogen Replacement Therapy; D015444:Exercise; D005223:Fats / Q000378:metabolism*; D005260:Female; D013006:Growth Hormone / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause / Q000378:metabolism*; D015431:Weight Loss
chemical_list: D005223:Fats; D013006:Growth Hormone